Phase 1 Two-Part (Open-label, Single Ascending Dose (Part 1) and Open-label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN).
This research is looking into a new treatment called NTLA-2001 for individuals living with a genetic condition known as hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). This condition can cause nerve damage, leading to various symptoms. This is a very early-stage study, meaning it's one of the first times this medicine is being given to people. The main goals are to check if the medicine is safe and if people can tolerate it well. We will also learn how the body uses and processes the medicine, and if it has any early effects on the disease. This first step is crucial to understand if NTLA-2001 has the potential to help people in the future.
At a glance
What is this study about?
This study is focused on a new potential medicine, NTLA-2001, for a specific inherited condition called hereditary transthyretin amyloidosis with polyneuropathy, often shortened to ATTRv-PN. In ATTRv-PN, abnormal proteins called amyloid build up in different parts of the body, including the nerves. This build-up can cause problems like tingling, numbness, pain, or weakness.
Because this is a very early-stage study, often called a 'Phase 1' study, the main purpose is to carefully check the safety of NTLA-2001. When a new medicine is first given to people, doctors need to understand how the body reacts to it, what side effects might happen, and what dose is safe. Researchers will also be looking at how the body absorbs, uses, and gets rid of the medicine, and if it shows any early signs of affecting the disease process.
While the primary focus is on safety, the study will also look at whether the medicine has any effect on the nerve problems associated with ATTRv-PN. This research is a vital step in developing new treatments for this condition, with the hope of finding ways to improve the lives of people affected by it.
Key takeaways
- This is an early-stage trial for a new medicine called NTLA-2001.
- It's for adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
- The main goal is to check how safe the medicine is and if people can tolerate it.
- Researchers will also look at how your body handles the medicine and any early effects.
- Participation is voluntary, and you can leave the study at any time.
Who may be eligible?
This study is looking for adult volunteers, aged 18 years or older, who have been diagnosed with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Both men and women are welcome to take part.
General health and specific details about your ATTRv-PN condition will be checked by the study doctors to make sure this trial is right for you and that you meet all the necessary requirements. This is to ensure your safety and that the study results are as clear as possible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I 18 years old or older?
- Have I been diagnosed with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN)?
- Am I able to attend regular appointments at the study clinic?
- Am I willing to follow all study instructions and guidelines?
- Am I comfortable with receiving a new, untested medicine?
What does participation involve?
If you decide to take part in this study, you would receive the new medicine, NTLA-2001. Because this is an early-stage study, the exact details of how long it lasts and how many visits are needed haven't been fully provided here, but typically, these studies involve regular visits to the clinic for medical check-ups, blood tests, and other assessments to monitor your health and the effects of the medicine. This will include keeping a close eye on any side effects and how your body is handling the treatment.
Throughout the study, you would have detailed assessments related to your polyneuropathy (nerve problems). While the total duration isn't specified, early studies often involve several months of active treatment and follow-up, possibly with a longer monitoring period after you stop taking the study medicine. All these steps are important to gather as much information as possible about NTLA-2001.
Potential risks and benefits
Locations (2)
- —UnverifiedFrance
- —UnverifiedSweden
Common questions
What is hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN)?
It's a genetic condition where abnormal proteins build up, often damaging nerves and causing symptoms like tingling, numbness, or weakness in your arms and legs.
What is NTLA-2001?
NTLA-2001 is a new medicine that is being tested as a potential treatment for ATTRv-PN. This study is one of the first times it's being given to people.
What does 'Phase 1' mean?
'Phase 1' means it's an early-stage study focused on checking the safety of the new medicine and how the human body handles it.
Will I definitely get better if I join this study?
Because this is an early study, we can't guarantee you'll feel better. The main aim is to understand if the medicine is safe and how it works, not primarily to treat your condition at this stage.
How long would I need to be involved in the study?
The exact length isn't specified, but early studies often involve several months of observation, tests, and follow-up appointments.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.